IL-33 reduces tumor growth in models of colorectal cancer with the help of eosinophils

References

• Davis BP, Rothenberg ME. Eosinophils and cancer. Cancer Immunol Res. 2014;2(1):1–12. doi:10.1158/2326-6066.CIR-13-0196.
   PubMed Web of Science ®Google Scholar
• Pretlow TP, Keith EF, Cryar AK, Bartolucci AA, Pitts AM, Pretlow TG, Kimball PM, Boohaker EA. Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res. 1983;43:2997–3000.
   PubMed Web of Science ®Google Scholar
• Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brünner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol. 1999;189(4):487–495. doi:10.1002/(SICI)1096-9896(199912)189:4<487::AID-PATH484>3.0.CO;2-I.
   PubMed Web of Science ®Google Scholar
• Harbaum L, Pollheimer MJ, Kornprat P, Lindtner RA, Bokemeyer C, Langner C. Peritumoral eosinophils predict recurrence in colorectal cancer. Mod Pathol. 2015;28(3):403–413. doi:10.1038/modpathol.2014.104.
   PubMed Web of Science ®Google Scholar
• Fernández-Aceñero MJ, Galindo-Gallego M, Sanz J, Aljama A. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer. 2000;88(7):1544–1548. doi:10.1002/(SICI)1097-0142(20000401)88:7<1544::AID-CNCR7>3.0.CO;2-S.
   PubMed Web of Science ®Google Scholar
• Prizment AE, Vierkant RA, Smyrk TC, Tillmans LS, Lee JJ, Sriramarao P, Nelson HH, Lynch CF, Thibodeau SN, Church TR, et al. Tumor eosinophil infiltration and improved survival of colorectal cancer patients: iowa women’s health study. Mod Pathol. 2016;29(5):516–527. doi:10.1038/modpathol.2016.42.
   PubMed Web of Science ®Google Scholar
• Reichman H, Itan M, Rozenberg P, Yarmolovski T, Brazowski E, Varol C, Gluck N, Shapira S, Arber N, Qimron U et al. Activated eosinophils exert antitumorigenic activities in colorectal cancer. Cancer Immunol Res. 2019;7(3):388–400. doi:10.1158/2326-6066.CIR-18-0494.
   PubMed Web of Science ®Google Scholar
• da Silva JM, Queiroz-Junior CM, Batista AC, Rachid MA, Teixeira MM, da Silva TA. Eosinophil depletion protects mice from tongue squamous cell carcinoma induced by 4-nitroquinoline-1-oxide. Histol Histopathol. 2014;29(3):387–396. doi:10.14670/HH-29.387.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Galdiero MR, Loffredo S, Lucarini V, Marone G, Mattei F, Marone G, Schiavoni G. Eosinophils: the unsung heroes in cancer? Oncoimmunology. 2017;7(2). doi:10.1080/2162402X.2017.1393134.
   PubMed Web of Science ®Google Scholar
• Legrand F, Driss V, Delbeke M, Loiseau S, Hermann E, Dombrowicz D, Capron M. Human eosinophils exert TNF-α and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J Immunol. 2010;185(12):7443–7451. doi:10.4049/jimmunol.1000446.
   PubMed Web of Science ®Google Scholar
• Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13(1):9–22. doi:10.1038/nri3341.
   PubMed Web of Science ®Google Scholar
• Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hämmerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells. Nat Immunol. 2015;16(6):609–617. doi:10.1038/ni.3159.
   PubMed Web of Science ®Google Scholar
• Andreone S, Spadaro F, Buccione C, Mancini J, Tinari A, Sestili P, Gambardella AR, Lucarini V, Ziccheddu G, Parolini I, et al. IL-33 promotes CD11b/CD18-mediated adhesion of eosinophils to cancer cells and synapse-polarized degranulation leading to tumor cell killing. Cancers. 2019;11(11):1664. doi:10.3390/cancers11111664.
   PubMed Web of Science ®Google Scholar
• Liew FY, Girard J-P, Turnquist HR. Interleukin-33 in health and disease. Nat Rev Immunol. 2016;16(11):676–689. doi:10.1038/nri.2016.95.
   PubMed Web of Science ®Google Scholar
• Kim JY, Lim S-C, Kim G, Yun HJ, Ahn S-G, Choi HS. Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity. Oncogene. 2015;34(38):4928–4938. doi:10.1038/onc.2014.418.
   PubMed Web of Science ®Google Scholar
• Afferni C, Buccione C, Andreone S, Galdiero MR, Varricchi G, Marone G, Mattei F, Schiavoni G. The pleiotropic immunomodulatory functions of IL-33 and its implications in tumor immunity. Front Immunol. 2018;9:2601. doi:10.3389/fimmu.2018.02601.
   PubMed Web of Science ®Google Scholar
• Li Y, Shi J, Qi S, Zhang J, Peng D, Chen Z, Wang G, Wang Z, Wang L. IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE2. J Exp Clin Cancer Res. 2018:37. doi:10.1186/s13046-018-0839-7.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Ji Y, Wang H, Zhang H, Zhou H. IL-33 promotes the development of colorectal cancer through inducing tumor-infiltrating ST2L+ regulatory T cells in mice. Technol Cancer Res Treat. 2018;17:153303381878009. doi:10.1177/1533033818780091.
   Web of Science ®Google Scholar
• He Z, Chen L, Souto FO, Canasto-Chibuque C, Bongers G, Deshpande M, Harpaz N, Ko HM, Kelley K, Furtado GC, et al. Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc Min/+ mice. Sci Rep. 2017;7(1):5520. doi:10.1038/s41598-017-05716-z.
   PubMed Web of Science ®Google Scholar
• Fang M, Li Y, Huang K, Qi S, Zhang J, Zgodzinski W, Majewski M, Wallner G, Gozdz S, Macek P, et al. IL33 promotes colon cancer cell stemness via JNK activation and macrophage recruitment. Cancer Res. 2017;77(10):2735–2745. doi:10.1158/0008-5472.CAN-16-1602.
   PubMed Web of Science ®Google Scholar
• Maywald RL, Doerner SK, Pastorelli L, De Salvo C, Benton SM, Dawson EP, Lanza DG, Berger NA, Markowitz SD, Lenz H-J, et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci U S A. 2015;112(19):E2487–2496. doi:10.1073/pnas.1422445112.
   PubMed Web of Science ®Google Scholar
• Mertz KD, Mager LF, Wasmer M-H, Thiesler T, Koelzer VH, Ruzzante G, Joller S, Murdoch JR, Brümmendorf T, Genitsch V, et al. The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice. Oncoimmunology. 2015;5:1. doi:10.1080/2162402X.2015.1062966.
   Web of Science ®Google Scholar
• Zhang Y, Davis C, Shah S, Hughes D, Ryan JC, Altomare D, Peña MMO. IL-33 promotes growth and liver metastasis of colorectal cancer in mice by remodeling the tumor microenvironment and inducing angiogenesis. Mol Carcinog. 2017;56(1):272–287. doi:10.1002/mc.22491.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhu L, Lu X, Bian H, Wu X, Yang W, Qin Q. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun. 2014;453(3):486–492. doi:10.1016/j.bbrc.2014.09.106.
   PubMed Web of Science ®Google Scholar
• Lucarini V, Ziccheddu G, Macchia I, La Sorsa V, Peschiaroli F, Buccione C, Sistigu A, Sanchez M, Andreone S, D’Urso MT, et al. IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. Oncoimmunology. 2017;6(6):e1317420. doi:10.1080/2162402X.2017.1317420.
   PubMed Web of Science ®Google Scholar
• Eissmann MF, Dijkstra C, Wouters MA, Baloyan D, Mouradov D, Nguyen PM, Davalos-Salas M, Putoczki TL, Sieber OM, Mariadason JM, et al. Interleukin 33 signaling restrains sporadic colon cancer in an interferon-γ-dependent manner. Cancer Immunol Res. 2018;6(4):409–421. doi:10.1158/2326-6066.CIR-17-0218.
   PubMed Web of Science ®Google Scholar
• O’Donnell C, Mahmoud A, Keane J, Murphy C, White D, Carey S, O’Riordain M, Bennett MW, Brint E, Houston A. An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer. Br J Cancer. 2016;114(1):37–43. doi:10.1038/bjc.2015.433.
   PubMed Web of Science ®Google Scholar
• Komai-Koma M, Wang E, Kurowska-Stolarska M, Li D, McSharry C, Xu D. Interleukin-33 promoting Th1 lymphocyte differentiation dependents on IL-12. Immunobiology. 2016;221(3):412–417. doi:10.1016/j.imbio.2015.11.013.
   PubMed Web of Science ®Google Scholar
• Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman W-H, Pagès F, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res. 2011;71(4):1263–1271. doi:10.1158/0008-5472.CAN-10-2907.
   PubMed Web of Science ®Google Scholar
• Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP, Weiner DB. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res. 2014;74(6):1789–1800. doi:10.1158/0008-5472.CAN-13-2729.
   PubMed Web of Science ®Google Scholar
• Lu B, Yang M, Wang Q. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy. J Mol Med. 2016;94(5):535–543. doi:10.1007/s00109-016-1397-0.
   PubMed Web of Science ®Google Scholar
• Larsen KM, Minaya MK, Vaish V, Peña MMO. The role of IL-33/ST2 pathway in tumorigenesis. Int J Mol Sci. 2018;19(9):2676. doi:10.3390/ijms19092676.
   PubMed Web of Science ®Google Scholar
• Hasenoehrl C, Feuersinger D, Sturm EM, Bärnthaler T, Heitzer E, Graf R, Grill M, Pichler M, Beck S, Butcher L, et al. G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1. Int J Cancer. 2018;142(1):121–132. doi:10.1002/ijc.31030.
   PubMed Web of Science ®Google Scholar
• Busch SE, Hanke ML, Kargl J, Metz HE, MacPherson D, Houghton AM. Lung cancer subtypes generate unique immune responses. J.I. 2016;197(11):4493–4503. doi:10.4049/jimmunol.1600576.
   Google Scholar
• Reichman H, Rozenberg P, Munitz A. Mouse eosinophils: identification, isolation, and functional analysis. Curr Protoc Immunol. 2017;119(1):14.43.1–14.43.22. doi:10.1002/cpim.35.
   PubMedGoogle Scholar
• Dyer KD, Moser JM, Czapiga M, Siegel SJ, Percopo CM, Rosenberg HF. Functionally competent eosinophils differentiated ex vivo in high purity from normal mouse bone marrow. J Immunol. 2008;181(6):4004–4009. doi:10.4049/jimmunol.181.6.4004.
   PubMed Web of Science ®Google Scholar
• Frei RB, Luschnig P, Parzmair GP, Peinhaupt M, Schranz S, Fauland A, Wheelock CE, Heinemann A, Sturm EM. Cannabinoid receptor 2 augments eosinophil responsiveness and aggravates allergen-induced pulmonary inflammation in mice. Allergy. 2016;71(7):944–956. doi:10.1111/all.12858.
   PubMed Web of Science ®Google Scholar
• Knuplez E, Curcic S, Theiler A, Bärnthaler T, Trakaki A, Trieb M, Holzer M, Heinemann A, Zimmermann R, Sturm EM, et al. Lysophosphatidylcholines inhibit human eosinophil activation and suppress eosinophil migration in vivo. Biochim Biophys Acta (BBA). 2020;1865(7):158686. doi:10.1016/j.bbalip.2020.158686.
   PubMed Web of Science ®Google Scholar
• Walker C, Rihs S, Braun RK, Betz S, Bruijnzeel PLB. Increased expression of CD11b and functional changes in eosinophils after migration across endothelial cell monolayers. J Immunol. 1993;150:4061–4071.
   PubMed Web of Science ®Google Scholar
• Valencia HA, Loffredo LF, Misharin AV, Berdnikovs S. Phenotypic plasticity and targeting of Siglec-FhighCD11clow eosinophils to the airway in a murine model of asthma. Allergy. 2016;71(2):267–271. doi:10.1111/all.12776.
   PubMed Web of Science ®Google Scholar
• Carmo LAS, Bonjour K, Ueki S, Neves JS, Liu L, Spencer LA, Dvorak AM, Weller PF, Melo RCN. CD63 is tightly associated with intracellular, secretory events chaperoning piecemeal degranulation and compound exocytosis in human eosinophils. J Leukoc Biol. 2016;100(2):391–401. doi:10.1189/jlb.3A1015-480R.
   PubMed Web of Science ®Google Scholar
• Palacios-Macapagal D, Connor J, Mustelin T, Ramalingam TR, Wynn TA, Davidson TS. Cutting edge: eosinophils undergo caspase-1–mediated pyroptosis in response to necrotic liver cells. J.I. 2017;199(3):847–853. doi:10.4049/jimmunol.1601162.
   Google Scholar
• Willebrand R, Voehringer D. IL-33-induced cytokine secretion and survival of mouse eosinophils is promoted by autocrine GM-CSF Ryffel B, editor. PLoS One. 2016;11(9):e0163751. doi:10.1371/journal.pone.0163751.
   PubMed Web of Science ®Google Scholar
• Stenfeldt A-L, Wennerås C. Danger signals derived from stressed and necrotic epithelial cells activate human eosinophils. Immunology. 2004;112(4):605–614. doi:10.1111/j.1365-2567.2004.01906.x.
   PubMed Web of Science ®Google Scholar
• Chen X, Lu K, Timko NJ, Weir DM, Zhu Z, Qin C, Mann JD, Bai Q, Xiao H, Nicholl MB, et al. IL‑33 notably inhibits the growth of colon cancer cells. Oncol Lett. 2018;16(1):769–774. doi:10.3892/ol.2018.8728.
   PubMed Web of Science ®Google Scholar
• Akimoto M, Maruyama R, Takamaru H, Ochiya T, Takenaga K. Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment. Nat Commun. 2016;7(1):1–15. doi:10.1038/ncomms13589.
   Web of Science ®Google Scholar
• Johansson K, Malmhäll C, Ramos-Ramírez P, Rådinger M. Bone marrow type 2 innate lymphoid cells: a local source of interleukin-5 in interleukin-33-driven eosinophilia. Immunology. 2018;153(2):268–278. doi:10.1111/imm.12842.
   PubMed Web of Science ®Google Scholar
• Malik A, Sharma D, Zhu Q, Karki R, Guy CS, Vogel P, T-D K. IL-33 regulates the IgA-microbiota axis to restrain IL-1α-dependent colitis and tumorigenesis. J Clin Invest. 2016;126(12):4469–4481. doi:10.1172/JCI88625.
   PubMed Web of Science ®Google Scholar
• Jia S, Li W, Liu P, Xu LX. A role of eosinophils in mediating the anti-tumour effect of cryo-thermal treatment. Sci Rep. 2019;9(1):13214. doi:10.1038/s41598-019-49734-5.
   PubMed Web of Science ®Google Scholar
• Chu VT, Beller A, Rausch S, Strandmark J, Zänker M, Arbach O, Kruglov A, Berek C. Eosinophils promote generation and maintenance of immunoglobulin-A-expressing plasma cells and contribute to gut immune homeostasis. Immunity. 2014;40(4):582–593. doi:10.1016/j.immuni.2014.02.014.
   PubMed Web of Science ®Google Scholar
• Hollande C, Boussier J, Ziai J, Nozawa T, Bondet V, Phung W, Lu B, Duffy D, Paradis V, Mallet V, et al. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. Nat Immunol. 2019;20(3):257. doi:10.1038/s41590-019-0321-5.
   PubMed Web of Science ®Google Scholar
• Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008;121(6):1484–1490. doi:10.1016/j.jaci.2008.04.005.
   PubMed Web of Science ®Google Scholar
• Bouffi C, Rochman M, Zust CB, Stucke EM, Kartashov A, Fulkerson PC, Barski A, Rothenberg ME. IL-33 markedly activates murine eosinophils by an NFκB-dependent mechanism differentially dependent upon an IL-4-driven autoinflammatory loop. J Immunol. 2013;191(8). doi:10.4049/jimmunol.1301465.
   PubMed Web of Science ®Google Scholar
• Nazaroff CD, Rank MA, Guo J, Wright BL, Ochkur SI, Jacobsen EA. Eosinophil subtypes defined by distinct gene expression and function. J Allergy Clin Immunol. 2019;143(2):AB289. doi:10.1016/j.jaci.2018.12.884.
   Web of Science ®Google Scholar
• Knuplez E, Krier‐Burris R, Cao Y, Marsche G, O’Sullivan J, Bochner BS. Frontline science: superior mouse eosinophil depletion in vivo targeting transgenic Siglec-8 instead of endogenous Siglec-F: mechanisms and pitfalls. J Leukoc Biol. 2020; doi:10.1002/JLB.3HI0120-381R.
   Web of Science ®Google Scholar
• Andersson P, Yang Y, Hosaka K, Zhang Y, Fischer C, Braun H, Liu S, Yu G, Liu S, Beyaert R, et al. Molecular mechanisms of IL-33–mediated stromal interactions in cancer metastasis. JCI Insight. 2018;3(20). doi:10.1172/jci.insight.122375
   Web of Science ®Google Scholar